MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why JANX Stock slipped -1.22% Today — RQD Quant Desk Flash
$17.83 -1.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $17.76
Janux Therapeutics Inc. (JANX) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.09B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $17.76 (-0.41%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JANX)Realized 20D OHLCV Swing Band: ±11.9%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY JANX SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)
FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 51.9 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$18.39-10.2% Next Q
41
Q2 (-2Q)Grade E$16.51+0.9% Next Q
38
Q3 (-1Q)Grade E$16.66+7% Next Q
36
CurrentGrade E$17.83-8.9% Hist 90D α
33
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a JANX Turnaround Squeeze
While JANX currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($17.60) and Max Pain ($18.72) forces dealer call-delta covering toward $37.11.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $JANX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “JANX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why JANX Stock slipped -1.22% Today — RQD Quant Desk Flash
Janux Therapeutics Inc. (JANX) slipped -1.22% to $17.83, trading at 25% of its 52-week range ($12.12 – $35.34). Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 25% of its 52-week range ($12.12 – $35.34) with RSI-14 at 51.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.9% around $17.83 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live JANX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JANX)
- ✓Walkthrough of JANX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
JANX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.08%▲ ASCENDING CHANNEL
2026-10-30O $17.92H $18.17L $17.13C $17.83VOL 540.0K
RES: $22.82SUP: $16.41SMA50: $17.60SMA200: $15.33
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
JANX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on JANX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for JANX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JANX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JANX)
Health Care Rank #862 of 1016
⚔️ MLTX vs JANX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (JANX vs. MLTX, CTY, HROW, MNKD)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Janux Therapeutics Inc. (JANX) ranks #862 by composite RQD confidence (33/100, grade E) and #353 by equity capitalization ($1.09B). Within this direct 5-issuer industry benchmark cohort, JANX leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with JANX at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| JANX
ACTIVE
Janux Therapeutics Inc. | E | 33/100 | — | — | -13.8% | -1.22% | $1.09B | Benchmark Subject |
| MLTX MoonLake Immunotherapeutics (Class A) | D | 46/100 | — | — | -35.0% | +2.11% | $1.07B | /mltx-vs-janx → |
| CTY City Therapeutics Inc. | C- | 61/100 | — | — | — | +2.26% | $1.11B | /cty-vs-janx → |
| HROW Harrow Inc. | B- | 71/100 | — | 75.1% | 42.9% | +2.04% | $1.12B | /hrow-vs-janx → |
| MNKD MannKind Corporation | C | 63/100 | — | 92.3% | 54.5% | +2.04% | $1.13B | /mnkd-vs-janx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001817713In its most recent audited fiscal period (FY2025, filed 2025-12-31), Janux Therapeutics Inc. (JANX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$113.6M, operating cash flow of -$82.2M, and free cash flow of -$83.3M (-88.5% YoY). On the balance sheet, JANX closed FY2025 with $1.00B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$113.6M | -$82.2M | -$83.3M | $1.00B | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$69.0M | -$43.8M | -$44.2M | $1.06B | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$58.3M | -$50.6M | -$50.6M | — | — |
3. JANX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs JANX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Janux Therapeutics Inc. (NASDAQ: JANX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $17.83 (-1.22% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, JANX ranks #862 in composite RQD confidence.
How does JANX compare to MLTX and CTY in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JANX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -13.8%. By comparison, MLTX (MoonLake Immunotherapeutics (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and CTY (City Therapeutics Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $1.11B). Among the 5-stock peer group, JANX leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for JANX?
Per JANX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817713), Janux Therapeutics Inc. generated $0 in revenue, -$113.6M in net income, and -$83.3M in free cash flow against $1.00B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is JANX trading relative to its 50-day, 200-day, and 52-week technical levels?
JANX last traded at $17.83 (-1.22% on volume of 905,885 shares), positioning the stock +1.31% above its 50-day simple moving average ($17.60) and +16.31% above its 200-day simple moving average ($15.33). Across its 52-week range of $12.12 to $35.34, JANX sits at the 24.6% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($15.71 to $19.95).
JANX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is JANX stock moving today?
Why JANX Stock slipped -1.22% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.